New England Research & Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $516K | Sell |
21,427
-25,483
| -54% | -$667K | 0.2% | 97 |
|
|
2026
Q1 | $1.32M | Sell |
46,910
-8,863
| -16% | -$236K | 0.56% | 60 |
|
|
2025
Q4 | $1.39M | Buy |
55,773
+9,548
| +21% | +$241K | 0.61% | 51 |
|
|
2025
Q3 | $1.18M | Sell |
46,225
-2,501
| -5% | -$61.7K | 0.54% | 65 |
|
|
2025
Q2 | $1.18M | Sell |
48,726
-6,901
| -12% | -$161K | 0.56% | 62 |
|
|
2025
Q1 | $1.41M | Sell |
55,627
-2,562
| -4% | -$67K | 0.72% | 49 |
|
|
2024
Q4 | $1.54M | Sell |
58,189
-16,274
| -22% | -$441K | 0.79% | 40 |
|
|
2024
Q3 | $2.15M | Buy |
74,463
+211
| +0.3% | +$6.16K | 1.01% | 30 |
|
|
2024
Q2 | $2.08M | Sell |
74,252
-6,017
| -7% | -$166K | 1% | 30 |
|
|
2024
Q1 | $2.23M | Buy |
80,269
+7,319
| +10% | +$203K | 1.09% | 27 |
|
|
2023
Q4 | $2.1M | Sell |
72,950
-5,900
| -7% | -$178K | 1.11% | 25 |
|
|
2023
Q3 | $2.62M | Sell |
78,850
-1,800
| -2% | -$63.7K | 1.49% | 15 |
|
|
2023
Q2 | $2.96M | Buy |
80,650
+5,675
| +8% | +$221K | 1.72% | 15 |
|
|
2023
Q1 | $3.06M | Buy |
74,975
+1,197
| +2% | +$51.7K | 1.79% | 11 |
|
|
2022
Q4 | $3.78M | Sell |
73,778
-340
| -0.5% | -$16.3K | 2.17% | 5 |
|
|
2022
Q3 | $3.24M | Sell |
74,118
-344
| -0.5% | -$16.7K | 2.04% | 6 |
|
|
2022
Q2 | $3.9M | Sell |
74,462
-5,309
| -7% | -$271K | 2.27% | 5 |
|
|
2022
Q1 | $4.13M | Buy |
79,771
+3,489
| +5% | +$181K | 2.14% | 7 |
|
|
2021
Q4 | $4.5M | Buy |
76,282
+325
| +0.4% | +$16.1K | 2.18% | 5 |
|
|
2021
Q3 | $3.27M | Buy |
75,957
+6,775
| +10% | +$300K | 1.71% | 9 |
|
|
2021
Q2 | $2.71M | Sell |
69,182
-2,927
| -4% | -$114K | 1.4% | 15 |
|
|
2021
Q1 | $2.61M | Sell |
72,109
-1,479
| -2% | -$52.5K | 1.43% | 14 |
|
|
2020
Q4 | $2.71M | Sell |
73,588
-13,654
| -16% | -$501K | 1.68% | 13 |
|
|
2020
Q3 | $3.04M | Sell |
87,242
-355
| -0.4% | -$12.4K | 2.2% | 6 |
|
|
2020
Q2 | $2.72M | Buy |
87,597
+19,288
| +28% | +$655K | 1.95% | 7 |
|
|
2020
Q1 | $2.12M | Buy |
68,309
+10,224
| +18% | +$348K | 1.81% | 12 |
|
|
2019
Q4 | $2.16M | Sell |
58,085
-184
| -0.3% | -$6.55K | 1.45% | 15 |
|
|
2019
Q3 | $1.99M | Buy |
58,269
+6,745
| +13% | +$245K | 1.44% | 13 |
|
|
2019
Q2 | $2.12M | Sell |
51,524
-263
| -0.5% | -$10.4K | 1.44% | 10 |
|
|
2019
Q1 | $2.09M | Sell |
51,787
-2,061
| -4% | -$82.5K | 1.41% | 9 |
|
|
2018
Q4 | $2.23M | Sell |
53,848
-896
| -2% | -$37.2K | 1.75% | 9 |
|
|
2018
Q3 | $2.29M | Buy |
54,744
+53
| +0.1% | +$2.04K | 1.49% | 10 |
|
|
2018
Q2 | $1.88M | Sell |
54,691
-3,549
| -6% | -$121K | 1.25% | 13 |
|
|
2018
Q1 | $1.96M | Sell |
58,240
-316
| -0.5% | -$10.9K | 1.31% | 13 |
|
|
2017
Q4 | $2.01M | Sell |
58,556
-14,300
| -20% | -$488K | 1.44% | 13 |
|
|
2017
Q3 | $2.47M | Sell |
72,856
-1,189
| -2% | -$38.2K | 1.81% | 4 |
|
|
2017
Q2 | $2.36M | Buy |
74,045
+11,173
| +18% | +$352K | 1.75% | 6 |
|
|
2017
Q1 | $2.04M | Buy |
62,872
+326
| +0.5% | +$10.3K | 1.57% | 8 |
|
|
2016
Q4 | $1.93M | Buy |
62,546
+289
| +0.5% | +$8.82K | 1.51% | 8 |
|
|
2016
Q3 | $2M | Buy |
62,257
+15,512
| +33% | +$519K | 1.68% | 8 |
|
|
2016
Q2 | $1.56M | Sell |
46,745
-1,960
| -4% | -$62.6K | 1.34% | 15 |
|
|
2016
Q1 | $1.37M | Buy |
48,705
+2,793
| +6% | +$79.8K | 1.16% | 18 |
|
|
2015
Q4 | $1.41M | Sell |
45,912
-1,687
| -4% | -$53.1K | 1.22% | 16 |
|
|
2015
Q3 | $1.42M | Buy |
47,599
+10,694
| +29% | +$343K | 1.35% | 12 |
|
|
2015
Q2 | $1.17M | Buy |
36,905
+531
| +1% | +$17.3K | 0.96% | 25 |
|
|
2015
Q1 | $1.2M | Sell |
36,374
-1,660
| -4% | -$52.8K | 1.03% | 20 |
|
|
2014
Q4 | $1.12M | Buy |
38,034
+5,007
| +15% | +$144K | 0.96% | 22 |
|
|
2014
Q3 | $927K | Sell |
33,027
-5,165
| -14% | -$145K | 0.81% | 39 |
|
|
2014
Q2 | $1.07M | Sell |
38,192
-10
| -0% | -$285 | 0.96% | 29 |
|
|
2014
Q1 | $1.16M | Buy |
38,202
+7,641
| +25% | +$228K | 1.07% | 26 |
|
|
2013
Q4 | $888K | Buy |
+30,561
| New | +$889K | 0.86% | 36 |
|
Other funds holding PFE
New England Research & Management's PFE Position: Q2 2026 in Review
New England Research & Management reduced its Pfizer (PFE) stake by 54% in Q2 2026, selling an estimated $667K and leaving 21,427 shares worth $516K. The position accounts for 0.2% of the portfolio, ranked #97.
New England Research & Management first reported a position in PFE in Q4 2013 and has held it in 51 quarters since. The position peaked at $4.5M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- New England Research & Management held 21,427 shares of Pfizer worth $516K as of Q2 2026.
- New England Research & Management sold 25,483 Pfizer shares in Q2 2026, an estimated $667K.
- Pfizer made up 0.2% of New England Research & Management's portfolio in Q2 2026, its #97 holding.
- New England Research & Management first reported a position in Pfizer in Q4 2013 and has held it in 51 quarters since.
- New England Research & Management's Pfizer position peaked at $4.5M in Q4 2021.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on New England Research & Management's 13F filing for Q2 2026, filed 9 Jul 2026.